Quick Facts: Uses of Strantel Plus

• Pinworm (Enterobiasis): Treatment for infections caused by Enterobius vermicularis.
• Roundworm (Ascariasis): Therapeutic action against infections caused by Ascaris lumbricoides.
• Hookworm: Used to address infections caused by specific hookworm species.

---

Strantel Plus, which contains pyrantel, is a medication utilized for the therapeutic management of intestinal parasitic infections. Its primary use is in the treatment of pinworm infection, medically known as enterobiasis. The medication works by promoting the removal of the parasites from the gastrointestinal system.

The drug is also an established treatment option for roundworm infections, or ascariasis. Additionally, it is used for addressing certain types of hookworm infections, including those caused by Ancylostoma duodenale and Necator americanus.

In clinical practice, a healthcare provider may determine that concurrent treatment of household members is necessary to help prevent the reoccurrence and spread of pinworms.

The eligibility profile for Strantel Plus (+Pyrantel) is defined solely for its target species, the dog, as documented by veterinary regulatory authorities. Use is strictly contraindicated in any animal with a known hypersensitivity to the active ingredients (Febantel, Praziquantel, Pyrantel) or excipients.

---

Eligibility and Restrictions

Population Status	Eligibility Rule
Age-Related Contraindication	Puppies less than 2 weeks of age and/or weighing less than 2 kg must not use this medicine.
Pharmacological Ban	Must not be used simultaneously with piperazine compounds or other cholinergic compounds.
Pregnancy Restriction	Contraindicated during the first and second trimesters of pregnancy. Use is permitted during the last trimester and throughout lactation.
Approved Use	Authorized for use in adult dogs and puppies meeting the minimum age and weight requirements. No explicit contraindications are listed for renal or hepatic impairment.

---

Connection to the overall eligibility profile: Official regulatory documents define the product's eligibility based on four critical boundaries: the Target Species, Hypersensitivity Status, Developmental Stage (minimum age/weight and pregnancy trimester), and Pharmacological Compatibility. This structured profile explicitly states which canine populations are allowed to use the medicine under standard conditions and which populations must not use it, strictly according to regulatory data.

Interactions with Other Medicines and Products

The interaction profile of Strantel Plus, a fixed-dose anthelmintic combination, focuses on pharmacodynamic antagonism and pharmacokinetic exposure modification, as documented in official regulatory labeling.

Contraindicated and Antagonistic Combinations

The co-administration of piperazine compounds must be avoided. Regulatory documents state that piperazines exhibit a pharmacodynamic antagonism against the pyrantel component of Strantel Plus, which interferes with its intended effect. Additionally, concurrent use with other cholinergic compounds carries a documented potential for toxicity and should be approached with caution as stated in product labeling.

Exposure-Modifying Interactions

Interactions involving metabolic pathways can affect the concentration of the active ingredients. Specifically, the co-administration of praziquantel (an ingredient in Strantel Plus) with medicines classified as Cytochrome P-450 enzyme inducers, such as phenobarbital or dexamethasone, can lead to a decrease in praziquantel plasma concentrations.

Administration Context Constraints

Official labeling confirms that the tablets can be administered with or without food, indicating that no timing-based interaction with meals exists. The documentation also states that no starvation or fasting is required before or after treatment.

The mechanism of action for this fixed-dose combination involves a coordinated, multiple-domain action on parasites, targeting both their neuromuscular system and cellular metabolism.

Pyrantel acts as a selective agonist at the parasite's nicotinic acetylcholine receptors ( nAchR), inducing continuous, spastic paralysis in susceptible nematodes. Concurrently, Praziquantel causes an immediate, massive influx of Ca^2+ ions through the Cestode tegument, resulting in generalized, uncontrollable tetanic muscle spasms and structural disruption. These actions physically compromise the parasite, which results in the physiological consequence of reduced motility and loss of mucosal attachment.

In the second domain, the active metabolites of Febantel function as dual inhibitors. They disrupt the formation of beta-tubulin microtubules, preventing the cellular transport essential for nutrient uptake. This cellular and metabolic inhibition prevents glucose absorption and ATP generation, which results in progressive starvation and the failure of essential physiological processes. This synergistic strategy promotes physiological disruption across different parasitic classes, leading to detachment and elimination from the host.

Administration Guidelines for Strantel Plus (+Pyrantel)

Strantel Plus, a fixed-dose combination anthelmintic for veterinary use, is administered as a single oral dose. The use protocol is based on the animal's body weight, establishing a precise administration rule.

Dosing and Frequency

Administration is defined by a required minimum dose for each active component. The standard regimen is a single tablet for every 10 kg (approximately 22 lbs) of body weight. This dosing ratio ensures the delivery of the minimum therapeutic levels of 5.0 mg/kg Pyrantel base, 15.0 mg/kg Febantel, and 5.0 mg/kg Praziquantel. The medication is delivered in a single event, meaning it is not administered as a prolonged course or cycle. Repeat use is generally not routine but may be considered by a veterinarian if a risk of re-infestation is present, with protocols for some parasites requiring retreatment at 21–26 day intervals.

Administration Context

Strantel Plus is intended for oral administration and can be given directly or concealed within food; fasting is neither necessary nor recommended. The oral tablets are scored and must be divided when necessary to ensure the calculated dose corresponds accurately to the animal's measured weight. This attention to weight determination is a procedural step.

Population-Specific Use Restrictions

Limits are established on its use based on population. The product is not permitted for use in very young puppies—specifically, those less than three weeks of age or weighing under 0.9 kg (approx. 2 lbs). Furthermore, while use in pregnant animals is not strictly prohibited, the specified dose must not be exceeded. A key procedural restriction dictates that the medication must not be administered simultaneously with piperazine compounds, as this combination may result in antagonism of the intended anthelmintic effect.

Research Evidence / Overview of Studies for Strantel Plus (+Pyrantel)

The research evidence for Strantel Plus (+Pyrantel) is primarily focused on the established clinical uses of its components, particularly Pyrantel, in managing intestinal parasitic infections in humans. The official evidence base for the specific three-drug combination (Febantel, Praziquantel, Pyrantel) in human populations remains limited, relying instead on the established, known actions of the individual active ingredients.

---

Evidence Base for Pinworm Infection (Enterobiasis)

The Pyrantel component was evaluated in studies relevant to pinworm infection, and the evidence base includes Randomized Controlled Trials (RCTs) and various comparative clinical trials. These studies primarily explored populations of school-aged children and adults. Research examined outcomes related to Parasite Clearance and the Cure Rate, an outcome axis defined by the measured conversion from a positive test for the parasite to a negative test. Findings indicate patterns related to the measured outcomes for the time frame required for converting from a positive diagnostic test to a negative one after the single-dose intervention.

---

Evidence Base for Roundworm (Ascariasis) and Hookworm Infections

The evidence base for the Pyrantel component was observed in studies relevant to Roundworm (Ascariasis) and Hookworm infections, including systematic reviews and large-scale efficacy studies derived from global Mass Drug Administration (MDA) campaigns. The key outcomes the studies explored included the quantified Faecal Egg Count Reduction (FECR) and the Cure Rate. Findings indicate patterns related to emerging resistance concerns, and official documentation cites that data are still emerging regarding parasitic resistance to anthelmintics in certain geographical areas.

---

What is Still Uncertain About the Research Landscape

Comparative evidence is lacking for the specific three-drug combination (Febantel, Praziquantel, Pyrantel) in human populations. The evidence level is high for the individual Pyrantel component, but key limitations exist regarding long-term effects which are not fully established. Specific data also remain insufficient for certain patient groups, including children under two years old and pregnant women in the early trimesters.

Key Studies & References

1. WHO Model List of Essential Medicines - Anthelmintics and Antiparasitics

Common questions about Strantel Plus (+Pyrantel) (FAQ)

Q: Is Strantel Plus (+Pyrantel) the same as just Pyrantel?

A: No, Strantel Plus is a fixed-dose combination product that contains three active ingredients: Febantel, Praziquantel, and Pyrantel. Therefore, it is distinct from a single-ingredient medicine containing only Pyrantel. The rationale for this combination is to address mixed parasitic infections, encompassing both nematodes and cestodes, as stated in official documents.

Q: Does Strantel Plus (+Pyrantel) cause drowsiness?

A: Drowsiness (somnolence) is listed as a possible effect in the official safety profiles of the Pyrantel component. These are classified under reported nervous system disturbances, along with dizziness. Reviewing the full official safety information is part of the overall usage guidance.

Q: What happens if I miss taking Strantel Plus (+Pyrantel) at the scheduled time?

A: The official administration protocol for Strantel Plus specifies that it is a single-dose medication, not a prolonged treatment cycle. Due to this, public regulatory guidance does not generally include a specific protocol for managing a missed single dose. Decisions regarding administration timing are based on the prescribed procedural steps.

Q: Can Strantel Plus (+Pyrantel) be taken on an empty stomach?

A: Official regulatory documents confirm that the medicine can be given with or without food. There is no official requirement for fasting or for taking the medicine at a specific time relative to meals.

Q: Is the Strantel component similar to other registered drugs?

A: The drug's active ingredients are categorized into recognized pharmacological classes by official bodies. Febantel is a Pro-Benzimidazole Derivative, Praziquantel is a Pyrazinoisoquinoline Derivative, and Pyrantel is a Tetrahydropyrimidine Derivative. Drugs within the same pharmacological class are defined as having similar basic mechanisms of action.

Q: Does Strantel Plus (+Pyrantel) have an impact on birth control pills?

A: Regulatory documents indicate that the Praziquantel component's concentrations can be lowered by medicines classified as Cytochrome P-450 enzyme inducers. Official warnings for related substances sometimes note potential concerns regarding contraceptive effectiveness when combining with enzyme-inducing substances.

Q: Are adverse events with Strantel Plus (+Pyrantel) commonly reported to regulatory bodies?

A: Official documents define the most frequently reported adverse effects as those related to Gastrointestinal and Nervous System disorders. However, the exact frequency of these events in the approved population is often categorized as less common or simply not specified in the core safety materials.

Q: What kind of research has been published on the combination of Strantel and Pyrantel?

A: Official product information notes that research is focused on the established uses of the individual components, like Pyrantel. However, regulatory authorities have stated that the official evidence base for the specific three-drug combination (Febantel, Praziquantel, Pyrantel) in human populations remains limited.

Q: How quickly can I expect Strantel Plus (+Pyrantel) to start working?

A: The onset of action on the parasite is described as rapid due to the paralyzing components, Pyrantel and Praziquantel, causing quick physical disruption. However, measured outcomes, such as parasite clearance, are typically assessed over a period of days to weeks in research studies.

Q: Does the medicine work by killing or paralyzing?

A: The medicine uses a multiple-action strategy. Pyrantel and Praziquantel components work by causing paralysis and spasms. Separately, the active metabolites of Febantel cause metabolic inhibition, which prevents nutrient absorption and causes the parasite to starve.

Q: Is fatigue a possible side effect of Strantel Plus (+Pyrantel)?

A: Fatigue has been reported in the general adverse event profiles for the Pyrantel component. Although it may not be listed among the most frequently documented side effects, it is an effect that has been noted in the wider body of safety data.

Q: Is there a recommended time of day for taking Strantel Plus (+Pyrantel)?

A: Official guidance states the medicine can be taken with or without food and does not require fasting. Therefore, no specific time of day (such as morning or evening) is officially specified as necessary for the medicine’s effectiveness.

Q: Is it normal to see changes in stool after taking this medication?

A: Changes in stool may occur due to the mechanism of action. The Pyrantel component paralyzes the worms, which are then naturally passed out of the body in the stool. Gastrointestinal disturbances like diarrhea, nausea, and vomiting are also listed in the adverse reaction profiles.

Q: Is the duration of treatment with Strantel Plus (+Pyrantel) typically short or long?

A: The treatment duration is considered short because the official administration protocol calls for a single oral dose only. It is not intended to be a prolonged course or cycle of medication.

Q: Does Strantel Plus (+Pyrantel) interact with any herbal supplements?

A: Specific herbal supplements are not listed in the product's official interaction documents. However, general safety guidance for many medications advises informing the prescribing professional of all nonprescription medicines and herbal products being used to check for potential compatibility issues.

Q: What are the signs that Strantel Plus (+Pyrantel) has worked?

A: Research studies measure the medicine's efficacy by achieving Parasite Clearance and Cure Rate, defined by the conversion from a positive diagnostic test to a negative one. For some infections, this may be accompanied by the resolution of related symptoms, and paralyzed worms may be seen being passed in the stool.

Q: Do official documents mention anything about repeated use of Strantel Plus (+Pyrantel)?

A: Official guidelines state that repeat use is generally not routine as the standard protocol is a single dose. However, re-treatment may be considered under professional guidance if there is a known risk of re-infestation, with certain protocols calling for specific intervals (e.g., 21 –26 days).

Official Storage and Disposal Requirements

This section summarizes the official requirements for storing and disposing of Strantel Plus tablets, as defined in regulatory labeling.

Storage Component	Requirement
Temperature	Does not require any special temperature storage conditions.
Packaging	Keep the blister in the outer carton.
Divided Tablets	Half tablets must be returned to the open blister space and the carton; must be used within 14 days.
Safety	Keep out of the sight and reach of children and animals.

Disposal Instructions:

All unused veterinary medicinal product and waste materials must be disposed of in accordance with local requirements and via designated collection schemes. The product should not be disposed of via wastewater or released into the environment due to potential aquatic toxicity. Persons handling the tablets should wash their hands afterwards.